SCHEMBL1574534

SCHEMBL1574534

O=C(Nc1ccc(Cl)cc1)N1CC(N2CCCCCC2)C1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.57
MAPT P10636 2/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2D6 P10635 1/20 0.57
CYP2C19 P33261 1/20 0.57
CCR2 P41597 1/20 0.56
KCNH2 Q12809 1/20 0.56
RAB9A P51151 7/20 0.55
NPC1 O15118 6/20 0.55
LMNA P02545 4/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
NFKB1 P19838 1/20 0.55
NFKB2 Q00653 1/20 0.55
RELA Q04206 1/20 0.55
ALOX5 P09917 1/20 0.53
TDP1 Q9NUW8 1/20 0.52
TAS1R3 Q7RTX0 1/20 0.51
TAS1R1 Q7RTX1 1/20 0.51
TAS1R2 Q8TE23 1/20 0.51
HTT P42858 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1575212 1.00 TP53 (0.57) TP53MAPTCYP3A4CYP2D6CYP2C19
SCHEMBL1575415 0.99 CCR2 (0.57) TP53MAPTCYP3A4CYP2D6CYP2C19
SCHEMBL1575248 0.86 LMNA (0.52) TP53MAPTCCR2KCNH2RAB9A
SCHEMBL1575593 0.86 EPHX2 (0.60) TP53MAPTCYP2C19RAB9ANPC1
SCHEMBL1575058 0.86 RAB9A (0.70) TP53MAPTCYP3A4CYP2D6CYP2C19
SCHEMBL1575430 0.86 RAB9A (0.70) TP53MAPTCYP3A4CYP2D6CYP2C19
SCHEMBL1574866 0.86 KMT2A (0.70) MAPTCYP3A4CYP2D6CYP2C19RAB9A
SCHEMBL1575343 0.86 NPSR1 (0.68) TP53MAPTCYP3A4CYP2D6CYP2C19
SCHEMBL1575841 0.86 NPSR1 (0.68) TP53MAPTCYP3A4CYP2D6CYP2C19
SCHEMBL1575380 0.86 KMT2A (0.70) MAPTCYP3A4CYP2D6CYP2C19RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB TP53 3220/4885MAPT 3908/4885CYP3A4 109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.